SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
12445026
Source:
http://linkedlifedata.com/resource/pubmed/id/12445026
Search
Subject
(
48
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0001563
,
umls-concept:C0031640
,
umls-concept:C0201734
,
umls-concept:C1708335
,
umls-concept:C1709518
,
umls-concept:C1979963
,
umls-concept:C1999216
,
umls-concept:C2003903
pubmed:dateCreated
2002-11-26
pubmed:abstractText
To assess the pharmacokinetic and pharmacodynamic profile of the novel PDE4 inhibitor V11294A (3-(3-cyclopentyloxy-4-methoxybenzyl)-6-ethylamino-8-isopropyl-3H purine hydrochloride) in healthy male volunteers.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/12445026-10373396
,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12445026-10712916
,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12445026-10885973
,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12445026-1426207
,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12445026-1493085
,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12445026-1634449
,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12445026-7812559
,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12445026-9163639
,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12445026-9476844
,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12445026-9578187
pubmed:language
eng
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/3',5'-Cyclic-AMP Phosphodiesterases
,
http://linkedlifedata.com/resource/pubmed/chemical/3-(3-cyclopentyloxy-4-methoxybenzyl)...
,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic Nucleotide...
,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphodiesterase Inhibitors
,
http://linkedlifedata.com/resource/pubmed/chemical/Purines
,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
pubmed:status
MEDLINE
pubmed:author
pubmed-author:BurchRonald MRM
,
pubmed-author:GaleDonna DonigiDD
,
pubmed-author:LacouturePeterP
,
pubmed-author:LandellsLinda JLJ
,
pubmed-author:MillerAlan JAJ
,
pubmed-author:NicholsTerryT
,
pubmed-author:O'ConnorBrian JBJ
,
pubmed-author:PageClive PCP
,
pubmed-author:RotshteynYakovY
,
pubmed-author:SmithKateK
,
pubmed-author:SpinaDomenicoD
,
pubmed-author:TonelliAlfredA
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
478-84
pubmed:dateRevised
2009-11-18
pubmed:articleTitle
Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers.
pubmed:affiliation
Purdue Frederick Inc., Norwalk, CT, USA.